HOLX Stock Analysis — Hologic
Sector: Healthcare
AI Verdict
Hologic trades at 17x next year's earnings with 76.6% EPS growth expected—cheap for the growth you're getting, and the clinical platform moat makes those expectations more credible than most in healthcare.
Competitive Moat
Hologic specializes in women's health diagnostics and medical imaging, with a defensible moat built on FDA-approved platforms and deep clinical relationships in breast and cervical cancer screening. Its installed base in mammography and proprietary assay technology create high switching costs for hospitals and labs.
Summary
Hologic is on watch due to analyst expectations for a massive 76.6% jump in earnings next year, far outpacing its modest 2.2% revenue growth.
Where It Stands
Hologic trades at 17.0x forward earnings, well below the healthcare sector median of 22x, while its trailing PEG ratio of 0.39 signals the current price is backed by strong expected growth.
Key Metrics
- Trailing P/E: 30.0x
- Forward P/E: 17.0x
- PEG Ratio: 0.39
- Earnings Growth: +0.8%
- Revenue Growth: +0.0%
- Market Cap: $17.0B
- 52-Week High: $76.07
- 52-Week Low: $51.90
Analyst Consensus
0 Buy · 20 Hold · 3 Sell (23 analysts)
Bull Case
With forward EPS growth forecast at 76.6% and a forward P/E of just 17.0x, you're paying a historically low multiple for a big earnings jump if consensus holds.
Bear Case
If the forward P/E reverts to the sector median of 22x but earnings disappoint, the stock could see a sharp derating given the 2.2% revenue growth is not supporting the EPS narrative.
Catalyst to Watch
Watch for quarterly earnings to confirm whether the projected 76.6% EPS growth is materializing, as any miss could quickly reset valuation expectations.